Caveolin-1 and AKT/mTOR Pathway in Kidney Cancer
Author Information
Author(s): Campbell L, Jasani B, Edwards K, Gumbleton M, Griffiths D F R
Primary Institution: Cardiff University
Hypothesis
Caveolin-1 interacts with the AKT/mTOR pathway to drive disease progression and metastasis in renal cell carcinoma (RCC).
Conclusion
The study found that the combined expression of caveolin-1 and activated components of the AKT/mTOR pathway predicts shorter disease-free survival in patients with renal cell carcinoma.
Supporting Evidence
- Patients with tumours coexpressing caveolin-1 and pAKT had a mean disease-free survival of 2.95 years compared to 6.14 years for those without.
- Coexpression of caveolin-1 and pS6 resulted in a mean survival of 1.45 years versus 5.96 years for those without.
- Patients with caveolin-1 positive tumours had significantly worse prognosis with a mean disease-free survival of 3.44 years.
Takeaway
This study shows that a protein called caveolin-1, when found together with certain other proteins, can help doctors figure out which kidney cancer patients might need more careful follow-up after treatment.
Methodology
Immunohistochemistry was performed on tissue microarrays from 174 clinically confined RCCs to assess the expression of caveolin-1 and components of the AKT/mTOR pathway.
Limitations
The study did not include patients with metastatic disease at presentation, which may limit the generalizability of the findings.
Participant Demographics
The median age of participants was 65 years, with 119 men and 55 women.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI: 1.15–3.92
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website